Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
oleh: Adil Adatia, MD, Bruce Ritchie, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-05-01 |
Deskripsi
We report an approximately 80% reduction in angioedema attacks with lanadelumab, a mAb targeting plasma kallikrein, in a case of hereditary angioedema with normal C1 inhibitor levels. This finding supports a central pathophysiologic role for kallikrein in hereditary angioedema with normal C1 levels and supports the need for prospective studies of lanadelumab use with this condition.